dc.contributor.author
Hofmann,Wolf Peter
dc.contributor.author
Mauss, Stefan
dc.contributor.author
Lutz, Thomas
dc.contributor.author
Schober, Andreas
dc.contributor.author
Böker, Klaus
dc.contributor.author
Moog, Gero
dc.contributor.author
Baumgarten, Axel
dc.contributor.author
Pfeiffer-Vornkahl, Heike
dc.contributor.author
Alshuth, Ulrich
dc.contributor.author
Hüppe, Dietrich
dc.contributor.author
Wedemeyer, Heiner
dc.contributor.author
Manns, Michael P.
dc.contributor.author
Schott, Eckart
dc.date.accessioned
2018-06-08T04:01:58Z
dc.date.available
2015-09-03T06:07:08.265Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/16452
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-20633
dc.description.abstract
Background and Aims Individualization of treatment with peginterferon alfa and
ribavirin in patients with chronic hepatitis C showed benefit in controlled
trials and was implemented in treatment guidelines to increase response rates
and to reduce side effects and costs. However, it is unknown whether
individualization was adopted in routine daily practice and whether it
translated into improved outcomes. Methods From a large noninterventional
cohort study, clinical and virologic response data of 10,262 HCV patients who
received peginterferon alfa-2a and ribavirin between 2003-2007 and 2008-2011
were analyzed. To account for treatment individualization, a matched-pair
analysis (2,997 matched pairs) was performed. Variation in treatment duration
and dosing of ribavirin were analyzed as indicators for individualization.
Results Sustained virological response (SVR) rates were similar between
2003-2007 and 2008-2011 (62.0% vs. 63.7%). Patients with comorbidities were
more abundant in the later period, (44.3% vs. 57.1%). The subsequent matched-
pair analysis demonstrated higher SVR rates in the 2008-2011 period (64.3%)
than in the 2003-2007 period (61.2%, p=0.008). More patients received
abbreviated or extended treatment regimens in the later than the earlier
period as an indicator of treatment individualization. To the same end,
ribavirin doses were higher in the later period (12.6 versus 11.6 mg/kg/day).
Factors independently associated with SVR included HCV genotype, low baseline
viral load, younger age, route of infection, absence of concomitant diseases,
lower APRI score, normal gamma-GT, higher ribavirin doses, no substitution for
drug abuse, treatment duration, and treatment in the 2008-2011 period.
Conclusions Treatment individualization with peginterferon alfa and ribavirin
was implemented in daily routine between 2003-2007 and 2008-2011, SVR rates
improved in the same period. These findings may be most relevant in resource-
limited settings.
de
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::616 Krankheiten
dc.title
Benefit of Treatment Individualization in Patients with Chronic Hepatitis C
Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional
Cohort Study
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
PLoS ONE. - 10 (2015), 7, Artikel Nr. e0134839
dcterms.bibliographicCitation.doi
10.1371/journal.pone.0134839
dcterms.bibliographicCitation.url
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0134839
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000023047
refubium.note.author
Der Artikel wurde in einer Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000005359
dcterms.accessRights.openaire
open access